David A. Siegel Clovis Oncology, Inc. Transaction History

Two Sigma Advisers, LP

12 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2022 Aug 15, 2022	SELL	$0.63 - $2.96 $43,533 - $204,536	-69,100 Reduced 58.31%	49,400 $89,000
Q1 2022 May 16, 2022	SELL	$1.43 - $3.14 $152,152 - $334,096	-106,400 Reduced 47.31%	118,500 $239,000
Q4 2021 Feb 14, 2022	BUY	$2.7 - $4.76 $429,300 - $756,840	159,000 Added 241.27%	224,900 $609,000
Q3 2021 Nov 15, 2021	BUY	$4.06 - $5.8 $267,554 - $382,220	65,900 New	65,900 $294,000
Q2 2020 Aug 14, 2020	SELL	$5.69 - $9.69 $142,819 - $243,219	-25,100 Closed	0 $0
Q1 2020 May 15, 2020	BUY	$3.77 - $11.0 $94,627 - $276,100	25,100 New	25,100 $160,000
Q4 2019 Feb 14, 2020	SELL	$3.0 - $16.43 $2.23 Million - $12.2 Million	-743,706 Closed	0 $0
Q3 2019 Nov 14, 2019	BUY	$3.93 - $15.35 $2.7 Million - $10.5 Million	686,400 Added 1197.78%	743,706 $2.92 Million
Q2 2019 Aug 14, 2019	BUY	$12.81 - $25.67 $449,707 - $901,171	35,106 Added 158.14%	57,306 $852,000
Q1 2019 May 15, 2019	BUY	$17.66 - $30.28 $392,052 - $672,216	22,200 New	22,200 $551,000
Q1 2018 May 15, 2018	SELL	$50.12 - $67.72 $2.43 Million - $3.28 Million	-48,400 Closed	0 $0
Q4 2017 Feb 14, 2018	BUY	$57.69 - $84.58 $2.79 Million - $4.09 Million	48,400	48,400 $3.29 Million

166

Ticker CLVS
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 144,480,000
Market Cap $13M
Description
Clovis Oncology, Inc., a biopharmaceutical company, focuses on acquiring, developing, and commercializing anti-cancer agents in the United States, Europe, and internationally. In the U.S., the company offers Rubraca (rucaparib), an oral small molecule inhibitor of poly ADP-ribose polymerase for recurrent epithelial ovarian, fallopian tube, or pr...

Get notified when there are updates to the investment portfolio of Two Sigma Advisers, LP, based on Form 13F filings with the SEC.

Stay updated on Two Sigma Advisers, LP and David A. Siegel with notifications on news.